Gender Differences in Colon Cancer Treatment

Oliver, JoAnn S.; Martin, Michelle Y.; Richardson, Lisa C.; Kim, Young; Pisu, Maria

doi:10.1089/jwh.2012.3988

Cited by 14 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some other age groups, we could even detect an opposite trend. The overall lower rate of administration of adjuvant chemotherapy has been described for other regions; however, it has not yet been described in Germany [18]. Whether this is mainly caused by the older age of women at the time of diagnosis which has previously been discussed, our results support these findings, as the lower rate of adjuvant chemotherapy was particularly apparent in the age group over 80 years.…”

Section: Discussionsupporting

confidence: 85%

Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients

Schmuck

Gerken

Teegen

et al. 2020

Langenbecks Arch Surg

View full text Add to dashboard Cite

Introduction Colorectal carcinomas represent the third most common cause of cancer-related deaths in Germany. Although the incidence is significantly higher in men compared with women and gender is a well-established crucial factor for outcome in other diseases, detailed gender comparisons for colon cancer are lacking. Methods This retrospective population-based cohort study included all patients diagnosed with colon cancer in Germany between 2000 and 2016 who were included in the common dataset of colorectal cancer patients from the quality conference of the German Cancer Society. We compared clinical, histopathological, and therapeutic characteristics as well as overall and recurrence-free survival. Results A total of 185,967 patients were included in the study, of which 85,685 were female (46.1%) and 100,282 were male (53.9%). The proportion of women diagnosed with colon cancer decreased from 2000 to 2016 (f: 26.6 to 40.1%; m: 24.9 to 41.9%; p < 0.001), and the proportion of very old patients was especially high in women (f: 27.3%; m: 15.6%; p < 0.001). The localization in women was more right-sided (f: 45.0%, m: 36.7%; p < 0.001), and women had a higher tumor grading and a higher UICC stage (especially stage III nodal-positive) at diagnosis of primary colon cancer (UICC III: f: 22.7%, m: 21.0%; p < 0.001). We could detect a significantly better overall (hazard ratio: 0.853, lower 95%: 0.841, upper 95%: 0.864; p < 0.001) and recurrence-free survival (hazard ratio: 0.857, lower 95%: 0.845, upper 95%: 0.868; p < 0.001) in women compared with men, even though women received chemotherapy less frequently compared with men (f: 26.1%, m: 28.1%; p < 0.001). Highlights • Women are older than men at diagnosis of primary colon cancer • The localization in women tends to be right-sided, and women tend to have a higher tumor grading and a higher UICC stage (especially stage III nodal-positive) • Women show a better overall and recurrence-free survival compared with men • Women receive chemotherapy less frequently than men do Electronic supplementary material The online version of this article (

show abstract

Section: Discussionsupporting

confidence: 85%

Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients

Schmuck

Gerken

Teegen

et al. 2020

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“… also reported that the rate of ACT was lower among older Stage III patients. Although the rate of ACT has been reported to be higher in men than in women , the rate in our study was higher in women, possibly due to sociodemographic factors. The rate of administration of ACT in our study was lower in patients with N1 tumours than in those with N2 tumours, indicating that physicians might have employed an observation strategy in cases of CRC with a small number of LN metastases; we also found low rates of ACT in patients with lymphatic invasion, as has been reported previously .…”

Section: Discussioncontrasting

confidence: 88%

Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The cumulative risk of developing colon cancer before 75 years is 1.51% and 1.12% for men and women, respectively, giving a rate of 1 in 66 men and 1 in 89 women to develop CC [ 2 ]. Despite recent advances in chemotherapy and radiotherapy for CC, surgical resection remains the primary treatment, but there are gender differences in CC treatment choices [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Female Colon Cancer Metastasis Pattern and Prognosis: A SEER-Based Study

Liu

Kang

Zheng

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

The purpose of this study was to compare the metastatic pattern and prognosis of female colon cancer (FCC) to that of male colon cancer (MCC) to ascertain the independent factors impacting the prognosis of patients with FCC. The data of the present study population were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Descriptive analysis, the Kaplan-Meier method, and the Cox regression were used to evaluated FCC characteristics and factors associated with prognosis. There were 56,442 patients diagnosed with FCC, of whom 8,817 had distant metastases. Compared to patients with nonmetastatic FCC, a greater proportion of metastatic FCC patients was less than 60 years of age, black race, and grade III-IV. The primary sites were mainly located on the left side and have more possibility to receive chemotherapy and radiotherapy. Compared to metastatic MCC, a higher proportion of metastatic FCC patients ranged over 60 years of age, black race, treated without chemotherapy, and insurance, while the primary site was located on the right side. Liver and lung were the two most common sites of solitary metastases in CC, and among patients with solitary metastases in CC, patients who had lung metastases had a better prognosis than those who developed other types of metastasizes. Patients with FCC with metastases of the liver had a worse prognosis than their MCC counterparts. Cox multivariate regression analysis showed that the risk ratio was higher in metastatic FCC patients compared to those without metastases. We report the survival comparison of metastatic FCC with nonmetastatic FCC through the SEER database. Our results suggest that it has unique clinicopathological features and differs from metastatic MCC. Furthermore, patients with liver metastatic FCC have a worse prognosis than those with MCC. Emphasis on screening for colon cancer in women and additional clinical care should be paid for, especially for patients with FCC with metastatic liver cancer.

show abstract

Gender Differences in Colon Cancer Treatment

Abstract: In Alabama, some gender differences in stage-specific colon cancer treatment are worth further scrutiny.

Cited by 14 publications

References 41 publications

Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients

Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients

Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study

Female Colon Cancer Metastasis Pattern and Prognosis: A SEER-Based Study

Contact Info

Product

Resources

About